Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase II, single-arm, multicenter study.
Shannon Puhalla
Consultant or Advisory Role - Celldex; MedImmune; Pfizer
Sharon Wilks
Consultant or Advisory Role - Eisai
Adam Brufsky
Consultant or Advisory Role - Eisai; Roche
Joyce O'Shaughnessy
Consultant or Advisory Role - Eisai
Lee Steven Schwartzberg
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Erhan Berrak
Employment or Leadership Position - Eisai
James Song
Employment or Leadership Position - Eisai
David Cox
Employment or Leadership Position - Eisai
Linda T. Vahdat
Consultant or Advisory Role - Eisai